期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

高血压治疗新药研究进展 被引量：17

Research progress of new drugs for the treatment of hypertension
原文传递
导出
摘要 药物治疗是高血压防控的重要手段,文章介绍了近些年在新药研制方面出现的几种新药,包括:新一代选择性醛固酮受体拮抗剂、直接肾素抑制剂、血管紧张素受体-脑啡肽酶双重阻滞剂、新型血管紧张素受体拮抗剂类药物和第三代β受体阻滞剂。 Drug treatment is an important means of prevention and control of hypertension,This paper introduces some new drugs in recent years in the development of new drugs appear, Including： a new generation of selective aldosterone receptor antagonist, direct renin inhibitors, angiotensin receptor- enkephalinase double blocker, a new angiotensin drugs and third receptor antagonist generation beta blocker.
作者 孙英贤
机构地区 中国医科大学附属第一医院心内科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第4期290-294,298,共6页 Chinese Journal of Practical Internal Medicine
关键词 高血压 药物治疗 hypertension medication
分类号 R544.1 [医药卫生—心血管疾病]
  • 相关文献

参考文献26

  • 1Lewington S, Clarke R, Q izilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies[J]. Lancet, 2002, 360(9349): 1903-1913.
  • 2Suzuki H, Shuto H, Shuto C, et al. Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than withoutj metabolic syndrome[J]. Ther Adv Cardiovasc Dis, 2012, 6(4): 141-147.
  • 3Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients withsystolic heart failure and mild symptoms[J]. N Engl J Med, 2011, 364(1): 11-21.
  • 4Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study[J]. Circulation, 2003, 108(15): 1831-1838.
  • 5Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial[J]. JAMA, 2013, 309(8): 781-791.
  • 6Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction[J]. N EnglJ Med, 2014, 370(15): 1383-1392.
  • 7Heshka J, Ruzicka M, Hiremath S, et al. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy[J]. J Am Soc Hypertens, 2010, 4(6): 295-301.
  • 8Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage[J]. Clin J Am Soc Nephrol, 2006, 1(2): 221-228.
  • 9Barrios V, Escobar C. Aliskiren: a new drug for an old problem[J]. Cardiovasc Hematol Agents Med Chem, 2010, 8 (1): 1 - 10.
  • 10Gradman AH, Weir MW, Arora V, et al. Aliskiren provides highly effective blood pressure reduction independent of age in patients with hypertension. Poster P-38 presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, 14-17 May 2008, New Orleans, LA, USA.

同被引文献130

  • 1陈燕,金岳伟.老年高血压患者服药依从性的影响因素分析及护理对策[J].中国医药指南,2008,6(16):87-87. 被引量：14
  • 2刘国树.β受体阻滞剂及其治疗高血压现状[J].中国药物应用与监测,2005,2(1):11-13. 被引量：25
  • 3刘力生.中国高血压防治指南2010[J].中国医学前沿杂志（电子版）,2011,3(5):42-93. 被引量：1227
  • 4无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2079
  • 5孙俊.抗高血压临床用药研究进展[J].中国药房,2007,18(20):1588-1590. 被引量：22
  • 6Black HR,Graff A,Shute D,et al.Valsartan,a new angiotensin II antagonist for the treatment of essentialhypertension:efficacy,tolerability and safetycompared to an angiotensin-converting enzyme inhibitor,lisinopril [J].J Hum Hypertens,1997,11(8):483-489.
  • 7NAVIGATOR Study Group,McMurry JJ,Holman RR,et al.Effect of valsartan on the incidence of diabetes and cardiovascular events[J].N Engl J Med,2010,362(15):1477-1490.
  • 8ONTARGET Investigatois,Yusuf S,Teo KK,et al.Telmisartan,ramipril,or both in patients at high risk for vascular events [J].N Engl J Med,2008,358(15):1547-1559.
  • 9Dahlof B,Devereux RB,Kjeldsen SE,et al.Cardiovascular mor- bidity and mortalityin the Losartan Intervention For Endpoint reduc- tion in hypertension study(LIFE):a randomised trial aganst atenolol[J].Lancet,2002,359(9311):995-1003.
  • 10Ay S A,Caker M,Karaman M,et al Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients:a novel effect to be explained with hyperfiltration?[J].Ren Fail,2013,35(3):357-360.

引证文献17

二级引证文献105

中国实用内科杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部